Company profile
Rani Therapeutics Holdings, Inc.
NASDAQ:RANIBiotechnology: Pharmaceutical Preparations
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06891287 | phase1 | recruiting | 2025-12-30 | 2026-12-01 | RANI Therapeutics | An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers. |
| NCT05164614 | phase1 | completed | 2022-02-21 | 2022-10-10 | RANI Therapeutics | Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule |
| NCT05890118 | phase1 | completed | 2023-08-30 | 2023-11-28 | RANI Therapeutics | Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule |
FDA applications (0)
No records yet.